# Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

> **NCT04511624** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** IBI112 dose1
- **DRUG:** IBI112 dose2
- **DRUG:** IBI112 dose3
- **DRUG:** IBI112 dose4
- **DRUG:** IBI112 dose5
- **DRUG:** IBI112 dose6
- **DRUG:** IBI112 dose7

## Key facts

- **NCT ID:** NCT04511624
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2022-07-22
- **Final completion:** 2022-07-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511624, "Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04511624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*